Graphite Bio announces two abstracts accepted for ASH 2022 annual meeting

LENZ Therapeutics, Inc.

Abstract #5965 describes beta-globin gene replacement strategy for beta-thalassemia using UltraHDR platform.
Abstract #3468 (poster) details single-cell RNA sequencing method to assess gene-editing outcomes in sickle cell disease.
CEO Josh Lehrer notes initial proof-of-concept data for nula-cel (SCD therapy) expected mid-2023.
Nula-cel is a first-in-human gene correction therapy; FDA granted Fast Track and Orphan Drug designations.
ASH meeting takes place Dec 10-13, 2022 in New Orleans.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.